Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial Posted on September 22, 2023September 25, 2024 by recce_com Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial
Recce Pharmaceuticals (ASX:RCE) paves its way to commercialisation with breakthrough antibiotic, R327 Posted on September 20, 2023September 25, 2024 by recce_com Recce Pharmaceuticals (ASX:RCE) paves its way to commercialisation with breakthrough antibiotic, R327
Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial Posted on August 28, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial
Recce Pharmaceuticals — R327 progressing in rapid infusion study Posted on August 24, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals — R327 progressing in rapid infusion study
Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial Posted on August 22, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial
Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds Posted on August 21, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds
Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections Posted on August 8, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections
Recce Pharmaceuticals awarded Australian patent for lead anti-infectives Posted on August 4, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals awarded Australian patent for lead anti-infectives
Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule Posted on July 24, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule
Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial Posted on July 19, 2023September 25, 2024 by officialtpss Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial
